Available Technologies

For information on technology available for licensing or commercialization, awards, or project information through the Case-Coulter Translational Research Partnership at Case Western Reserve University, please contact the Case-Coulter program leadership and we would be pleased to answer any questions you may have. This is a partial list, so please feel free to contact the team to learn more about these or additional opportunities. When available, technologies with one-page overviews are linked to the technology title.

Set Up a 30-minute Phone Call

Quick Links:


Gastrointestinal Liner for Diversion of Intestinal Contents

Steve Schomisch, assistant professor of surgery
Jeff Marks, professor of surgery

People sometimes develop a wound connecting their intestine to their skin. This complication is incredibly debilitating and costly. The intestinal contents leak out onto the skin causing injury to the skin and muscle, dehydration and malnutrition, and there is currently no way to stop it. The researchers are developing a novel management strategy to greatly reduce the leak, which reduces cost of care and helps patients recover faster.

Learn more about the Gastrointestinal Liner.

Enabling Closed-loop Baroreflex Activation in the Treatment of Refractory Hypertension

Jonathan Baskin, associate professor of otology head and neck and staff physician at the Louis Stokes Cleveland VA Medical Center
Dustin Tyler, the Kent H Smith Professor II of Biomedical Engineering
Gilles Pinault, assistant professor of surgery and staff physician at University Hospitals
Steve Majerus, research scientist at the Louis Stokes Cleveland VA Medical Center

High blood pressure or hypertension is a serious health care problem associated with considerable morbidity and mortality. Physicians rely heavily on drugs to treat hypertension, but there is a significant and growing population that is drug-resistant. Their approach employs an implanted neuromodulatory system to address this unmet need. They have demonstrated efficacy of their novel stimulation system in an acute human model, however, a vital element in this treatment modality is sensing blood pressure.

Minimally Invasive Interfascicular Nerve Stimulation (MiiNS) System for Chronic Pain Management

Dustin Tyler, Kent H. Smith Professor, biomedical engineering
Salim Hayek, professor, anesthesiology

This is a drug-free technology to provide targeted, comfortable, worry-free relief to people suffering from long-term pain. The discomfort and emotional stress from pain affects a person’s activity, sleep, and ability to live a healthy life, leading to other serious health problems. Our Minimally Invasive Interfascicular Nerve Stimulation (MiiNS) technology provides a targeted, personally customized and comfortable treatment without side effects, addiction or surgical procedures. MiiNS can be implanted by a doctor during a simple office visit to provide long lasting pain relief.

Learn more about MiiNS.

3-D Ultrasound Imaging for Ophthalmology

Faruk Orge, professor of ophthalmology and visual sciences at the School of Medicine and pediatric division chief of ophthalmology at University Hospitals Cleveland Medical Center
David Wilson, professor of biomedical engineering

This technology will be the first high-resolution, 3-D microscopic ultrasound system to provide novel visualizations of eye structures to better understand pathophysiology, plan treatments and assess treatment results. Ultrasound is an effective ophthalmic imaging method that allows structures behind the iris, including the lens and ciliary body, as well as key portions of the aqueous outflow system, to be seen. This region of the eye plays a critical role in glaucoma—which affects over 2.7 million people in the United States alone—and cataract, which are leading causes of reversible and irreversible blindness.

Learn more about the 3-D ultrasound imaging technology.


TraumaChek: A Field-Deployable Dielectric Coagulometer for Comprehensive Assessment of Trauma-Induced Coagulopathy

Anirban Sen Gupta, professor biomedical engineering
Sanjay Ahuja, professor of pediatrics

TraumaChekTM is a miniaturized, multichannel, portable, handheld blood coagulation analyzer for early, rapid, and comprehensive assessment of trauma-induced coagulopathy to guide hemorrhage control, transfusion, and resuscitative management of trauma at the point-of-injury by first responders and at the point-of-care by hospital clinicians.

Learn more about TraumaCheck.

MIRCA-Dx: A Revolutionary New Way to Assess Targeted and Genetic Therapies for Inherited Red Cell Disorders

Umut Gurkan, the Warren E. Rupp Associate Professor of mechanical engineering
Pedram Mohseni, the Goodrich Professor of Engineering Innovation and chair of electrical, computer and systems engineering
Sanjay Ahuja, professor of pediatric hematology/oncology and staff physician at University Hospitals

New genetic therapies can correct unhealthy red blood cells, but can’t assess the health and functional properties of the newly made red cells in a patient. The researchers offer a novel reproducible, portable diagnostic test for physicians and pharmaceutical companies to measure how well the new genetic therapies work for a red blood-cell disorder, such as sickle cell disease.

Novel Positron Emission Tomography (PET) Imaging Agent for Tumor Detection and Treatment

Susann Brady-Kalnay, professor of molecular biology and microbiology
James Basilion, professor of radiology biomedical engineering and pathology

Specific tumor detection is critically important in cancer imaging to avoid unnecessary biopsies to exclude false-positive findings and to allow treatment—or redirection of treatment—at earlier stages of the disease. Positron Emission Tomography (PET) imaging agents that specifically recognize tumor cells are necessary for improved imaging and subsequent evaluation of therapeutic efficacy independent of their metabolic rates. PTPµ is a novel imageable biomarker that can be used to specifically and more comprehensively detect and monitor aggressive invasive and metastatic tumors.

Learn more about using PET imaging to detect tumors.

Point-of-care Device for Monitoring and Diagnosis of Oral Cancer

Aaron Weinberg, associate dean for research, chair of the Department of Biological Sciences and professor
Umut Gurkan, assistant professor of mechanical and aerospace engineering
Santosh Ghosh, senior research associate

Oral cancer kills thousands in the United States and hundreds of thousands worldwide. Early detection is key to improved survival. Oral cancer is now diagnosed by tissue biopsy, followed by pathology review.
But biopsies are expensive, painful, can cause complications and are impractical, should monitoring be required.

The team’s novel technology builds on a recent discovery that the two proteins produced in early stages of oral cancer change their ratios in cancerous cells, and that the ratio could be used as a non-invasive diagnostic tool. The researchers have developed a point-of-care microfluidic device which, when connected to a smartphone, obtains ratio results within 15 minutes.

Advantages include the ability to: non-invasively swab and diagnose a lesion for cancer while the patient waits; determine if a biopsy is necessary; permit pre-malignant lesions to be monitored; perform the test in any dental or ear, nose and throat clinic as part of oral health check-up; and obtain results at one-tenth the cost of a biopsy and pathology review.

Learn more about the point-of-care device.

Robust Nanobubble Contrast Agents for Real-time Ultrasound Guided Prostate Cancer Biopsy

Agata Exner, professor of radiology and biomedical engineering
Jim Basilion, professor of radiology and biomedical engineering

This technology will enable a more efficient and effective prostate cancer diagnosis while building on the existing biopsy workflow and clinical ultrasound imaging technology. The nanobubble imaging agent will specifically target prostate cancer cells and serve as a beacon guiding the urologist, in real time, to possible tumors. Nanobubble-guided biopsies could identify tumors more accurately and could lead to fewer procedures, thus reducing risk, lowering costs and shortening the time to diagnosis and treatment. 
Sickle cell disease biochip blood-cell adhesion test for emerging anti-adhesive therapies (OPTIONED)
Umut Gurkan, assistant professor of mechanical and aerospace engineering; and Jane Little, professor of medicine in the Department of Hematology and Oncology

Sickle cell disease biochip technology is a new microfluidic blood test that measures the stickiness of blood cells to blood vessel walls. This new blood test can be used as a companion diagnostic test platform for emerging anti-adhesive therapies to allow effective, personalized treatment and care for patients living with sickle cell disease.

Learn more about the nanobubble contrast.


BAFF CAR-NK Cells for Therapy of B Cell Malignancies

Reshmi Parameswaran, assistant professor of medicine
Umut Gurkan, the Warren E. Rupp Associate Professor of mechanical engineering

B cell Activating Factor Chimeric Antigen Receptor-Natural Killer (BAFF CAR-NK) cells can specifically kill B cell cancers in a very effective manner with minimum side effects. This is a potential therapy to address patients not responding to current cancer treatments.

Learn more about BAFF CAR-NK cells.

BG34-200: A Potent Immunotherapeutic for Melanoma, Osteosarcoma, Pancreatic Cancer and Other Solid Tumor Cancers

Mei Zhang, research assistant professor, biomedical engineering
Alex Huang, professor of pediatrics and pathology

A significant fraction of patients with solid tumor cancers in metastatic and advanced settings do not respond to immunotherapies due to a lack of T-cell-inflamed tumor microenvironment. This botanical-derived non-toxic BG34-200 molecule can be intravenously injected to modulate macrophages and create a tumor microenvironment that is vital for the generation of antitumor T-cell responses. The team is launching a clinical trial targeting canine metastatic osteosarcoma (OS) to collect key and gap data in preparation for a First-In-Human clinical trial targeting pediatric and AYA OS.

Learn more about BG34-200.

NeutroStat: Neutrophil-targeted Nanomedicine for Treating Venous Thromboembolism (VTE)

Evi Stavrou, assistant professor of medicine and staff physician at the Louis Stokes Cleveland VA Medical Center
Anirban Sen Gupta, professor of biomedical engineering

The NeutroStat technology consists of a nanoparticle loaded with specific neutrophil signal inhibitory drugs. The nanoparticle can specifically target activated neutrophil-platelet complexes that are the hallmark of developing clot niche in venous thrombosis and weakens the clot growth by decreasing neutrophil-driven thrombotic mechanisms. 

Learn more about NeutroStat.

Drug-Free Targeted Prostate Cancer Treatment with TNT (Targeted Nanobubble Therapy)

Agata Exner, professor of radiology and biomedical engineering
Jim Basilion, professor of radiology and biomedical engineering

Drug free, low toxicity prostate cancer treatment using nanobubbles are targeted to the prostate specific membrane antigen (PSMA) biomarker overexpressed on prostate tumor cells. The nanobubbles are injected into the bloodstream and specifically seek out only the cancer cells. Once inside the target cell, the NBs remain trapped and can be excited with an ultrasound pulse. Exposure to ultrasound results in collapse of the bubbles, leading to a highly focused mechanical disruption of the cancer cells and cell death. The approach, which we call TNT – targeted nanobubble therapy - can fit into the existing clinical work flow and can be carried out with standard clinical ultrasound equipment. TNT can treat tumors without severe side effects, as it will be effective only when NBs are sonicated and will destroy only the cancer cells and not the surrounding healthy cells.

Learn more about Targeted Nanobubble Therapy.

Photosorb: Engineered Sunscreen With Single, Multifunctional Active Ingredient

Vijay Krishna, assistant staff in Cleveland Clinic’s Department of Biomedical Engineering
Edward Maytin, staff in Cleveland Clinic’s Department of Dermatology

Every year, more than one million new cases of skin cancer, including melanoma, are diagnosed in the United States. The primary cause is exposure to ultraviolet radiation (UV) from sunlight. Sunscreens can block UV, but increasing concerns about the health and environmental risks of chemical sunscreens now on the market underscores an urgent need for safer, more effective alternatives. A team from biomedical engineering and dermatology at Cleveland Clinic is developing a novel sunscreen (PhotoSorb) that appears to be safer and more stable than current sunscreens, and also has the potential to actually prevent skin cancers.

Learn more about Photosorb.

Pharmacokinetic-pharmacodynamic-efficacy and Safety Studies of Humanized Monoclonal Antibodies to Treat Inflammatory and Immune Diseases

Yunmei Wang, associate professor of medicine
Xin Yu, the F. Alex Nason Professor of biomedical engineering
Daniel Simon, professor of medicine and chief clinical and scientific officer and president of University Hospitals Cleveland Medical Center

They developed novel monoclonal antibodies (mAbs) against a key extracellular signaling protein, the myeloid related protein-14 (MRP-14, aka S100A9), that acts as a potent driver of inflammation and thrombosis. MRP-14 has been implicated in the pathogenesis of several human diseases including SLE, thrombosis, atherosclerosis and acute lung injury.

HXB-319 as an Engineered Mesenchymal Stem Cell (MSC) Based Treatment for the Rare/Orphan Autoimmune Disorder Goodpasture Syndrome

Hulya Bukulmez, associate professor of pediatrics and staff physician at MetroHealth
John Chae, professor of biomedical engineering and vice president of research and sponsored programs at MetroHealth

They have developed a novel cell therapy (HXB-319) based on naked MSCs, engineered to enhance immune responses to reduce inflammation and its resulting organ damage. The work proposed will help to advance HXB-319 cell therapy toward clinical use by targeting systemic autoimmune inflammatory diseases that cause end-stage organ damage such as pulmonary hemorrhage and end-stage kidney disease.

Learn more about engineered MSC cells.